269 related articles for article (PubMed ID: 23091202)
1. Potential lifetime cost-effectiveness of catheter-based renal sympathetic denervation in patients with resistant hypertension.
Dorenkamp M; Bonaventura K; Leber AW; Boldt J; Sohns C; Boldt LH; Haverkamp W; Frei U; Roser M
Eur Heart J; 2013 Feb; 34(6):451-61. PubMed ID: 23091202
[TBL] [Abstract][Full Text] [Related]
2. Cost-effectiveness and clinical effectiveness of catheter-based renal denervation for resistant hypertension.
Geisler BP; Egan BM; Cohen JT; Garner AM; Akehurst RL; Esler MD; Pietzsch JB
J Am Coll Cardiol; 2012 Oct; 60(14):1271-7. PubMed ID: 22981547
[TBL] [Abstract][Full Text] [Related]
3. Cost effectiveness of renal denervation therapy for the treatment of resistant hypertension in the UK.
Gladwell D; Henry T; Cook M; Akehurst R
Appl Health Econ Health Policy; 2014 Dec; 12(6):611-22. PubMed ID: 25086585
[TBL] [Abstract][Full Text] [Related]
4. Cost-effectiveness of renal denervation therapy for the treatment of resistant hypertension in The Netherlands.
Henry TL; De Brouwer BF; Van Keep MM; Blankestijn PJ; Bots ML; Koffijberg H
J Med Econ; 2015 Jan; 18(1):76-87. PubMed ID: 25367314
[TBL] [Abstract][Full Text] [Related]
5. Cost-Effectiveness of Renal Denervation Therapy for Treatment-Resistant Hypertension: A Best Case Scenario.
Chowdhury EK; Reid CM; Zomer E; Kelly DJ; Liew D
Am J Hypertens; 2018 Sep; 31(10):1156-1163. PubMed ID: 30010694
[TBL] [Abstract][Full Text] [Related]
6. Results of a Markov model analysis to assess the cost-effectiveness of statin therapy for the primary prevention of cardiovascular disease in Korea: the Korean Individual-Microsimulation Model for Cardiovascular Health Interventions.
Kang HY; Ko SK; Liew D
Clin Ther; 2009 Dec; 31(12):2919-30; discussion 2916-8. PubMed ID: 20110032
[TBL] [Abstract][Full Text] [Related]
7. Potential cost-effectiveness of therapeutic drug monitoring in patients with resistant hypertension.
Chung O; Vongpatanasin W; Bonaventura K; Lotan Y; Sohns C; Haverkamp W; Dorenkamp M
J Hypertens; 2014 Dec; 32(12):2411-21; discussion 2421. PubMed ID: 25255395
[TBL] [Abstract][Full Text] [Related]
8. Orthostatic function after renal sympathetic denervation in patients with resistant hypertension.
Lenski M; Mahfoud F; Razouk A; Ukena C; Lenski D; Barth C; Linz D; Laufs U; Kindermann I; Böhm M
Int J Cardiol; 2013 Nov; 169(6):418-24. PubMed ID: 24157238
[TBL] [Abstract][Full Text] [Related]
9. Cost-effectiveness of intensive lipid lowering therapy with 80 mg of atorvastatin, versus 10 mg of atorvastatin, for secondary prevention of cardiovascular disease in Canada.
Wagner M; Goetghebeur M; Merikle E; Pandya A; Chu P; Taylor DC
Can J Clin Pharmacol; 2009; 16(2):e331-45. PubMed ID: 19531812
[TBL] [Abstract][Full Text] [Related]
10. Estimating the cost-effectiveness of onabotulinumtoxinA for neurogenic detrusor overactivity in the United States.
Carlson JJ; Hansen RN; Dmochowski RR; Globe DR; Colayco DC; Sullivan SD
Clin Ther; 2013 Apr; 35(4):414-24. PubMed ID: 23522658
[TBL] [Abstract][Full Text] [Related]
11. Cost effectiveness of prostacyclins in pulmonary arterial hypertension.
Roman A; Barberà JA; Escribano P; Sala ML; Febrer L; Oyagüez I; Sabater E; Casado MA
Appl Health Econ Health Policy; 2012 May; 10(3):175-88. PubMed ID: 22452448
[TBL] [Abstract][Full Text] [Related]
12. Cost-effectiveness of a cardiovascular disease primary prevention programme in a primary health care setting. Results of the Polish part of the EUROACTION project.
Sović N; Pająk A; Jankowski P; Duenas A; Kawecka-Jaszcz K; Wolfshaut-Wolak R; Stepaniak U; Kawalec P
Kardiol Pol; 2013; 71(7):702-11. PubMed ID: 23907903
[TBL] [Abstract][Full Text] [Related]
13. Economic evaluation of clopidogrel in acute coronary syndrome patients without ST-segment elevation in Greece: a cost-utility analysis.
Kourlaba G; Fragoulakis V; Maniadakis N
Appl Health Econ Health Policy; 2012 Jul; 10(4):261-71. PubMed ID: 22667992
[TBL] [Abstract][Full Text] [Related]
14. Cost-effectiveness of 3-years of adjuvant imatinib in gastrointestinal stromal tumors (GIST) in the United States.
Sanon M; Taylor DC; Parthan A; Coombs J; Paolantonio M; Sasane M
J Med Econ; 2013; 16(1):150-9. PubMed ID: 22762291
[TBL] [Abstract][Full Text] [Related]
15. [Safety and short-term efficacy of renal sympathetic denervation in the treatment of resistant hypertension].
Jiang XJ; Liang T; Dong H; Peng M; Ma WJ; Guan T; Zhang HM; Bian J; Xu B; Gao RL
Zhonghua Yi Xue Za Zhi; 2012 Dec; 92(46):3265-8. PubMed ID: 23328511
[TBL] [Abstract][Full Text] [Related]
16. A health economic analysis of screening and optimal treatment of nephropathy in patients with type 2 diabetes and hypertension in the USA.
Palmer AJ; Valentine WJ; Chen R; Mehin N; Gabriel S; Bregman B; Rodby RA
Nephrol Dial Transplant; 2008 Apr; 23(4):1216-23. PubMed ID: 18359872
[TBL] [Abstract][Full Text] [Related]
17. Long-term cost-effectiveness model of interferon beta-1b in the early treatment of multiple sclerosis in the United States.
Pan F; Goh JW; Cutter G; Su W; Pleimes D; Wang C
Clin Ther; 2012 Sep; 34(9):1966-76. PubMed ID: 22906738
[TBL] [Abstract][Full Text] [Related]
18. Screen-and-treat strategies for albuminuria to prevent cardiovascular and renal disease: cost-effectiveness of nationwide and targeted interventions based on analysis of cohort data from the Netherlands.
Boersma C; Gansevoort RT; Pechlivanoglou P; Visser ST; van Toly FF; de Jong-van den Berg LT; de Jong PE; Postma MJ;
Clin Ther; 2010 Jun; 32(6):1103-21. PubMed ID: 20637965
[TBL] [Abstract][Full Text] [Related]
19. Can hip protector use cost-effectively prevent fractures in community-dwelling geriatric populations?
Honkanen LA; Mushlin AI; Lachs M; Schackman BR
J Am Geriatr Soc; 2006 Nov; 54(11):1658-65. PubMed ID: 17087691
[TBL] [Abstract][Full Text] [Related]
20. Cost effectiveness of intrathecal drug therapy in management of chronic nonmalignant pain.
Kumar K; Rizvi S; Bishop S
Clin J Pain; 2013 Feb; 29(2):138-45. PubMed ID: 22699140
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
